Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018

  • ID: 4586018
  • Report
  • 81 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AusBio Ltd
  • EpiVax Inc
  • iBio Inc
  • Moderna Therapeutics Inc
  • Ology Bioservices Inc
  • Shionogi & Co Ltd
  • MORE
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.

Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

Report Highlights:

This latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AusBio Ltd
  • EpiVax Inc
  • iBio Inc
  • Moderna Therapeutics Inc
  • Ology Bioservices Inc
  • Shionogi & Co Ltd
  • MORE
Introduction

Report Coverage

Influenza A Virus, H7N9 Subtype Infections - Overview

Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development

AusBio Ltd

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Genentech Inc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Moderna Therapeutics Inc

NanoViricides Inc

Ology Bioservices Inc

Sanofi Pasteur SA

Shionogi & Co Ltd

VirionHealth Ltd

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections - Drug Profiles

AT-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baloxavir marboxil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (split virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (whole virion) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-2009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-7529 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-126LAIV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VH-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H7N9 Subtype Infections - Dormant Projects

Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones

Featured News & Press Releases

Sep 08, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 6th European Scientific Working Group in Influenza Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by iBio Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Moderna Therapeutics Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shionogi & Co Ltd, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by VirionHealth Ltd, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H1 2018

Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AusBio Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • Cocrystal Pharma Inc
  • EpiVax Inc
  • Genentech Inc
  • iBio Inc
  • Inovio Pharmaceuticals Inc
  • Medicago Inc
  • Medigen Vaccine Biologics Corp
  • Moderna Therapeutics Inc
  • NanoViricides Inc
  • Ology Bioservices Inc
  • Sanofi Pasteur SA
  • Shionogi & Co Ltd
  • VirionHealth Ltd
  • Visterra Inc
  • Vivaldi Biosciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll